The global drug-eluting balloon catheters market size was estimated to be USD 0.61423 billion in 2023 and is expected to reach at USD 1.6452 billion by 2033 with a CAGR of 9.37% during the forecast period 2023-2033. Growing prevalence of heart diseases, surge in preference of minimally invasive procedures, rising adoption of balloon catheters in angioplasty surgeries, higher efficiency of drug-eluting balloon catheters over drug-eluting stents, increasing technological advancements, growing product approvals by regulatory bodies, and rising introduction of innovative drug-eluting balloon are some of the key factors boosting the market growth.
Rising introduction of innovative drug-eluting balloon is predicted to boost the market growth during the forecast period. For instance, in August 2022, BD has announced the commencement of a groundbreaking first-in-human precision trial aimed at evaluating the safety and effectiveness of the peripheral sirolimus drug-coated balloon (DCB). The primary objective of these trials is to assess sirolimus' efficacy as a potential future treatment option for individuals suffering from peripheral artery disease (PAD).
By Drug, Paclitaxel was the highest revenue-grossing segment in the global drug-eluting balloon catheters market in 2022 owing to well established presence of paclitaxel-eluting balloon catheters, growing focus on the development of advanced catheters, and surge in approvals of advanced devices. For instance, in May 2022, Medtronic has revealed that the U.S. Food and Drug Administration (FDA) has given its approval for IN.PACT 018, a paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) balloon catheter. This device is intended for the interventional treatment of Peripheral Arterial Disease (PAD) specifically in the superficial femoral and popliteal arteries. Additionally, Sirolimus is predicted to grow at fastest CAGR during the forecast period owing to its effectiveness in treating vascular restenosis than paclitaxel due to its higher anti-proliferation action on hypoxic cells associated with atherosclerosis.
By Indication, Peripheral Intervention was the highest revenue-grossing segment in the global drug-eluting balloon catheters market in 2022 owing to rising prevalence of peripheral artery disease, increasing launch of new devices for peripheral indication, and growing focus on the development of advanced devices by major market players. Additionally, Coronary Intervention is predicted to grow at fastest CAGR during the forecast period owing to growing prevalence of cardiovascular diseases, surge in technological advancements, and increasing product approvals by regulatory bodies. For instance, in September 2022, The US FDA has granted approval to Advanced NanoTherapies for its SirPlux Duo Drug Coated Balloon, designed for the treatment of coronary artery disease in vessels with a diameter less than 3.0 mm.
By End User, Ambulatory Surgical Centers & Hospitals was the highest revenue-grossing segment in the global drug-eluting balloon catheters market in 2022 owing to surge in number of hospitals conducting angioplasty surgeries, rising number of patients visiting to the hospitals for the treatment after disease diagnosis, growing healthcare expenditures, increasing prevalence of various cardiovascular diseases, and surge in product approvals by regulatory bodies. For instance, in November 2020, Boston Scientific Corporation announced that its drug-eluting balloon catheter, Ranger, has obtained approval from the U.S. Food & Drug Administration (FDA). The catheter is specifically developed to address patients with Peripheral Artery Disease (PAD) affecting the Proximal Popliteal Artery (PPA) and Superficial Femoral Artery (SFA). Additionally, Specialty clinics & catheterization laboratories is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of specialty clinics & catheterization laboratories, and growing prevalence of coronary & peripheral vascular diseases.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of heart diseases, rising healthcare expenditures, growing demand for minimally invasive procedures, increasing launch of advanced products, and surge in device approvals by regulatory bodies. For instance, in May 2022, MedAlliance's SELUTION SLR drug-eluting balloon has been granted investigational device exemption approval by the FDA. This innovative device offers a controlled and sustained drug release specifically designed for treating below-the-knee indications in patients with peripheral artery disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of coronary & peripheral artery diseases, shift in preference towards minimally invasive procedures, surge in healthcare infrastructure, growing technological advancements, and increasing regulatory approvals. For instance, in January 2021, MicroPort Medical (Group) Co., Ltd. has been granted the EU CE mark for their Reewarm PTX Drug Coated Balloon PTA catheter. This approval is specifically for the device's use in percutaneous transluminal angioplasty to treat femoral popliteal artery conditions.
Rising introduction of innovative drug-eluting balloon is predicted to boost the market growth during the forecast period. For instance, in August 2022, BD has announced the commencement of a groundbreaking first-in-human precision trial aimed at evaluating the safety and effectiveness of the peripheral sirolimus drug-coated balloon (DCB). The primary objective of these trials is to assess sirolimus' efficacy as a potential future treatment option for individuals suffering from peripheral artery disease (PAD).
By Drug, Paclitaxel was the highest revenue-grossing segment in the global drug-eluting balloon catheters market in 2022 owing to well established presence of paclitaxel-eluting balloon catheters, growing focus on the development of advanced catheters, and surge in approvals of advanced devices. For instance, in May 2022, Medtronic has revealed that the U.S. Food and Drug Administration (FDA) has given its approval for IN.PACT 018, a paclitaxel-coated Percutaneous Transluminal Angioplasty (PTA) balloon catheter. This device is intended for the interventional treatment of Peripheral Arterial Disease (PAD) specifically in the superficial femoral and popliteal arteries. Additionally, Sirolimus is predicted to grow at fastest CAGR during the forecast period owing to its effectiveness in treating vascular restenosis than paclitaxel due to its higher anti-proliferation action on hypoxic cells associated with atherosclerosis.
By Indication, Peripheral Intervention was the highest revenue-grossing segment in the global drug-eluting balloon catheters market in 2022 owing to rising prevalence of peripheral artery disease, increasing launch of new devices for peripheral indication, and growing focus on the development of advanced devices by major market players. Additionally, Coronary Intervention is predicted to grow at fastest CAGR during the forecast period owing to growing prevalence of cardiovascular diseases, surge in technological advancements, and increasing product approvals by regulatory bodies. For instance, in September 2022, The US FDA has granted approval to Advanced NanoTherapies for its SirPlux Duo Drug Coated Balloon, designed for the treatment of coronary artery disease in vessels with a diameter less than 3.0 mm.
By End User, Ambulatory Surgical Centers & Hospitals was the highest revenue-grossing segment in the global drug-eluting balloon catheters market in 2022 owing to surge in number of hospitals conducting angioplasty surgeries, rising number of patients visiting to the hospitals for the treatment after disease diagnosis, growing healthcare expenditures, increasing prevalence of various cardiovascular diseases, and surge in product approvals by regulatory bodies. For instance, in November 2020, Boston Scientific Corporation announced that its drug-eluting balloon catheter, Ranger, has obtained approval from the U.S. Food & Drug Administration (FDA). The catheter is specifically developed to address patients with Peripheral Artery Disease (PAD) affecting the Proximal Popliteal Artery (PPA) and Superficial Femoral Artery (SFA). Additionally, Specialty clinics & catheterization laboratories is predicted to grow at fastest CAGR during the forecast period owing to the increasing number of specialty clinics & catheterization laboratories, and growing prevalence of coronary & peripheral vascular diseases.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of heart diseases, rising healthcare expenditures, growing demand for minimally invasive procedures, increasing launch of advanced products, and surge in device approvals by regulatory bodies. For instance, in May 2022, MedAlliance's SELUTION SLR drug-eluting balloon has been granted investigational device exemption approval by the FDA. This innovative device offers a controlled and sustained drug release specifically designed for treating below-the-knee indications in patients with peripheral artery disease. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of coronary & peripheral artery diseases, shift in preference towards minimally invasive procedures, surge in healthcare infrastructure, growing technological advancements, and increasing regulatory approvals. For instance, in January 2021, MicroPort Medical (Group) Co., Ltd. has been granted the EU CE mark for their Reewarm PTX Drug Coated Balloon PTA catheter. This approval is specifically for the device's use in percutaneous transluminal angioplasty to treat femoral popliteal artery conditions.
Segmentation: Drug-eluting Balloon Catheters Market Report 2022 - 2033
Drug-eluting Balloon Catheters Market Analysis & Forecast by Drug 2022 - 2033 (Revenue USD Mn)
- Sirolimus
- Paclitaxel
- Others
Drug-eluting Balloon Catheters Market Analysis & Forecast by Indication 2022 - 2033 (Revenue USD Mn)
- Peripheral Intervention
- Coronary Intervention
Drug-eluting Balloon Catheters Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Mn)
- Specialty Clinics & Catheterization Laboratories
- Ambulatory Surgical Centers & Hospitals
- Others
Drug-eluting Balloon Catheters Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Mn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Drug-eluting Balloon Catheters Market: Drug Estimates & Trend Analysis
8. Drug-eluting Balloon Catheters Market: Indication Estimates & Trend Analysis
9. Drug-eluting Balloon Catheters Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Drug-eluting Balloon Catheters Market
12. Europe Global Drug-eluting Balloon Catheters Market
13. Asia Pacific Global Drug-eluting Balloon Catheters Market
14. Latin America Global Drug-eluting Balloon Catheters Market
15. MEA Global Drug-eluting Balloon Catheters Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- MedAlliance
- MicroPort Medical Co. Ltd.
- Koninklijke Philips N.V.
- BD
- Boston Scientific Corporation
- Medtronic
- B. Braun SE
- Merial Life Sciences Pvt. Ltd.
- Cordis
- Advanced NanoTherapies
- BIOTRONIK
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | August 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 0.61 Billion |
| Forecasted Market Value ( USD | $ 1.65 Billion |
| Compound Annual Growth Rate | 9.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
